HUP9801817A3 - Dolastatin derivatives, their preparation and use - Google Patents

Dolastatin derivatives, their preparation and use

Info

Publication number
HUP9801817A3
HUP9801817A3 HU9801817A HUP9801817A HUP9801817A3 HU P9801817 A3 HUP9801817 A3 HU P9801817A3 HU 9801817 A HU9801817 A HU 9801817A HU P9801817 A HUP9801817 A HU P9801817A HU P9801817 A3 HUP9801817 A3 HU P9801817A3
Authority
HU
Hungary
Prior art keywords
preparation
dolastatin derivatives
dolastatin
derivatives
Prior art date
Application number
HU9801817A
Other languages
English (en)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of HUP9801817A2 publication Critical patent/HUP9801817A2/hu
Publication of HUP9801817A3 publication Critical patent/HUP9801817A3/hu
Publication of HU228073B1 publication Critical patent/HU228073B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HU9801817A 1995-06-07 1996-06-03 Új dolasztatin-származékok, elõállításuk, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények HU228073B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002393 WO1996040752A1 (en) 1995-06-07 1996-06-03 Novel dolastatin derivatives, their preparation and use

Publications (3)

Publication Number Publication Date
HUP9801817A2 HUP9801817A2 (hu) 1998-11-30
HUP9801817A3 true HUP9801817A3 (en) 1999-06-28
HU228073B1 HU228073B1 (hu) 2012-09-28

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9801910A HU228071B1 (hu) 1995-06-07 1996-06-03 Dolasztatinszármazékok, elõállításuk és felhasználásuk
HU9801817A HU228073B1 (hu) 1995-06-07 1996-06-03 Új dolasztatin-származékok, elõállításuk, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU9801910A HU228071B1 (hu) 1995-06-07 1996-06-03 Dolasztatinszármazékok, elõállításuk és felhasználásuk

Country Status (33)

Country Link
US (1) US5831002A (hu)
EP (2) EP0871656B1 (hu)
JP (2) JP4221062B2 (hu)
KR (2) KR100437986B1 (hu)
CN (2) CN1182154C (hu)
AR (2) AR003136A1 (hu)
AT (2) ATE224910T1 (hu)
AU (2) AU725170B2 (hu)
BG (2) BG102125A (hu)
BR (2) BR9609424A (hu)
CA (2) CA2219819C (hu)
CO (2) CO4700527A1 (hu)
CZ (2) CZ293683B6 (hu)
DE (2) DE69623472T2 (hu)
DK (2) DK0871656T3 (hu)
ES (2) ES2188759T3 (hu)
HR (2) HRP960257A2 (hu)
HU (2) HU228071B1 (hu)
IL (2) IL122215A (hu)
MX (2) MX9709147A (hu)
MY (2) MY119042A (hu)
NO (2) NO317670B1 (hu)
NZ (2) NZ310444A (hu)
PL (2) PL185762B1 (hu)
PT (2) PT871656E (hu)
RO (2) RO118953B1 (hu)
SI (2) SI0832104T1 (hu)
SK (1) SK282466B6 (hu)
TR (2) TR199701545T1 (hu)
TW (2) TW508357B (hu)
UA (2) UA46776C2 (hu)
WO (2) WO1996040751A1 (hu)
ZA (2) ZA964710B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
WO2002088298A1 (en) 2001-04-27 2002-11-07 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
WO2003051835A2 (en) * 2001-12-18 2003-06-26 Proteologics, Inc. Methods and compositions for the inhibition of viral release
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
US8568637B2 (en) 2004-08-02 2013-10-29 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
NZ580271A (en) * 2007-04-12 2011-03-31 Scinopharm Taiwan Ltd Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
AU2011352145A1 (en) 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP6581774B2 (ja) * 2011-05-27 2019-09-25 アンブルックス, インコーポレイテッドAmbrx, Inc. 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
UA45304C2 (uk) * 1992-05-20 2002-04-15 Басф Аг Похідні пептиду або їх солі, фармацевтична композиція
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
DE69623472T2 (de) 2003-08-21
NZ310444A (en) 1999-11-29
HRP960257A2 (en) 1998-02-28
AU6124296A (en) 1996-12-30
IL122215A0 (en) 1998-04-05
CA2219818C (en) 2008-05-20
SK282466B6 (sk) 2002-02-05
US5831002A (en) 1998-11-03
ZA964710B (en) 1997-12-08
PL323726A1 (en) 1998-04-14
NO975711L (no) 1998-01-30
AR003136A1 (es) 1998-07-08
CZ293682B6 (cs) 2004-07-14
NO975711D0 (no) 1997-12-05
EP0871656B1 (en) 2002-09-25
ZA964711B (en) 1997-12-08
AU725170B2 (en) 2000-10-05
ATE224910T1 (de) 2002-10-15
CN1182154C (zh) 2004-12-29
CA2219819A1 (en) 1996-12-19
EP0871656A1 (en) 1998-10-21
CA2219819C (en) 2008-05-20
CN1187199A (zh) 1998-07-08
DK0871656T3 (da) 2003-01-27
CA2219818A1 (en) 1996-12-19
PL185763B1 (pl) 2003-07-31
RO119783B1 (ro) 2005-03-30
JPH11504652A (ja) 1999-04-27
WO1996040752A1 (en) 1996-12-19
MY124487A (en) 2006-06-30
CZ376597A3 (cs) 1998-06-17
TW424096B (en) 2001-03-01
EP0832104B1 (en) 2002-09-04
DE69623992T2 (de) 2003-05-22
CZ376397A3 (cs) 1998-06-17
KR19990022583A (ko) 1999-03-25
AR003427A1 (es) 1998-08-05
JPH11504653A (ja) 1999-04-27
EP0832104A1 (en) 1998-04-01
IL122216A (en) 2002-02-10
TW508357B (en) 2002-11-01
KR19990022582A (ko) 1999-03-25
AU6124196A (en) 1996-12-30
UA46775C2 (uk) 2002-06-17
CZ293683B6 (cs) 2004-07-14
HUP9801817A2 (hu) 1998-11-30
NO317670B1 (no) 2004-11-29
NO975710L (no) 1998-02-02
RO118953B1 (ro) 2004-01-30
PL185762B1 (pl) 2003-07-31
MX9709146A (es) 1998-03-31
ATE223431T1 (de) 2002-09-15
UA46776C2 (uk) 2002-06-17
HRP960277A2 (en) 1997-10-31
AU725164B2 (en) 2000-10-05
ES2188759T3 (es) 2003-07-01
CN1187198A (zh) 1998-07-08
DK0832104T3 (da) 2003-01-06
BR9609424A (pt) 2000-03-28
PT871656E (pt) 2002-12-31
JP4221062B2 (ja) 2009-02-12
HUP9801910A2 (hu) 1999-01-28
MY119042A (en) 2005-03-31
SI0832104T1 (en) 2003-08-31
MX9709147A (es) 1998-03-31
WO1996040751A1 (en) 1996-12-19
SI0871656T1 (en) 2003-08-31
NO318384B1 (no) 2005-03-14
ES2186783T3 (es) 2003-05-16
DE69623472D1 (de) 2002-10-10
SK165397A3 (en) 1998-10-07
HUP9801910A3 (en) 1999-06-28
DE69623992D1 (de) 2002-10-31
HU228073B1 (hu) 2012-09-28
PL323723A1 (en) 1998-04-14
HU228071B1 (hu) 2012-09-28
BG102125A (en) 1998-09-30
BR9609423A (pt) 1999-06-29
CN1182153C (zh) 2004-12-29
TR199701544T1 (xx) 1998-03-21
JP3957751B2 (ja) 2007-08-15
TR199701545T1 (xx) 1998-04-21
CO4700526A1 (es) 1998-12-29
IL122216A0 (en) 1998-04-05
NO975710D0 (no) 1997-12-05
KR100437986B1 (ko) 2004-09-18
CO4700527A1 (es) 1998-12-29
KR100437985B1 (ko) 2004-09-18
IL122215A (en) 2001-08-26
BG102152A (en) 1998-09-30
NZ310443A (en) 1999-10-28
PT832104E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
HUP9801910A3 (en) Dolastatin derivatives, their preparation and use
IL116851A0 (en) 3-arylidene-2-oxindole derivatives their preparation and use
IL118825A (en) Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use
EP0728749A3 (en) Triazine derivatives, their preparation and their application
EP0710667B8 (de) Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
HUP9801139A3 (en) Polysiloxane-polyol macromers, their preparation and their use
IL118442A0 (en) Triazolymethyl-cyclopentanols their preparation and use
IL114795A0 (en) N-benzylindole- and benmzopyrazole derivatives their preparation and use
SI1019358T1 (en) 3,3-diarylpropylamines , their use and preparation
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
IL117807A0 (en) 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives their preparation and use
AU5772396A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
IL118441A0 (en) Triazolymethyl-oxiranes their preparation and use
AU7095296A (en) Phosphorylamides, their preparation and use
IL118443A0 (en) Cycloalkane-benzylidene derivatives their preparation and use
GR3031710T3 (en) Oxazolidinone derivatives, their preparation and therapeutical use
IL116710A0 (en) Substituted 2-phenylpyridines their preparation and use
IL116712A0 (en) Substituted 2-phenylpyridines their preparation and use
SG49960A1 (en) Dyes, processes for their preparation and their use
IL123092A0 (en) Pyrazol-4-ylbenzoyl derivatives their preparation and use
IL116711A0 (en) Substituted 2-phenylpyridines their preparation and use
IL118444A0 (en) Mercapto-triazolyl-silanes their preparation and use
IL122686A0 (en) Benzylhydroxylamines their preparation and use
EP0744125A3 (en) Iodine complex and its application

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG, DE

Free format text: FORMER OWNER(S): ABBOTT GMBH & CO. KG, DE; BASF AKTIENGESELLSCHAFT, DE

MM4A Lapse of definitive patent protection due to non-payment of fees